Personalized treatment for depression using therapy and medication

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to improve treatment outcomes for individuals with Major Depressive Disorder and Persistent Depressive Disorder by identifying which patients are more likely to benefit from cognitive-behavioral therapy (CBT) versus antidepressant medication. By utilizing clinical predictors and biomarkers, the researchers hope to match patients with the most effective treatment modality for their specific symptoms and history. The study will involve participants who have been diagnosed with depression and have not responded adequately to previous treatments. The goal is to enhance remission rates and reduce the burden of depression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* a diagnosis of MDD or PDD established with the Structured Clinical Interview for DSM-5 (SCID-5), and depression being the primary problem requiring clinical attention (judgement of intake clinician).
* a minimum current severity of 14 on the 17-item Hamilton Rating Scale for Depression (HRSD-17)
* a cumulative duration of depression of at least two months (this will exclude short-lasting first depressive episodes that do not require treatment of this intensity), age 18 or more (no upper limit)
* capacity to provide informed consent.

Exclusion Criteria

* lifetime diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, or current alcohol or drug use disorder
* pregnancy
* recent receipt of adequate trial of psychological treatment (10 or more sessions in the past 12 months)
* recently introduced antidepressant medication (new antidepressant in past 12 weeks or dose increase in the past 6 weeks)
* previous non-response to two or more of study medications
* acute suicide risk (MADRS suicide item≥4)
* current psychotic symptoms.

Where it's running

• Nova Scotia Health Authority
  Halifax, Nova Scotia, Canada Recruiting

Study contacts

• Principal investigator: Rudolf Uher, MD, PhD — Nova Scotia Health Authority
• Study coordinator: Rudolf Uher, MD, PhD
• Email: rudolf.uher@nshealth.ca
• Phone: 1-902-473-7209

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• Accelerated vs Standard iTBS for Major Depression

  This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.

  Recruiting Military Hospital 175 · Ho Chi Minh City · NCT07768397

• Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD

  This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.

  Recruiting Phase 3 Khyber Medical University Peshawar · Islamabad, Capital and 2 other locations · NCT07703722

• Magnesium Bisglycinate Added to Your Depression Treatment

  This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.

  Recruiting All India Institute of Medical Sciences, Bhubaneswar · Bhubaneswar, Odisha · NCT07633080

• Motif XCS System for treatment-resistant depression

  This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.

  Recruiting at 4 sites Motif Neurotech, Inc. · Atlanta, Georgia and 3 other locations · NCT07594483

• A Phase 3 test of DT120 for major depressive disorder

  DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.

  Recruiting at 23 sites Phase 3 Definium Therapeutics US, Inc. · Little Rock, Arkansas and 25 other locations · NCT07592689

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.